REUTERS: Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life of previously untreated lung cancer patients.The company said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to chemotherapy alone in patients with advanced non-small cell lung cancer, the most common form of the disease.
Data presented at a medical meeting last month showed that about 40per cent of patients with advanced lung cancer on the Opdivo-Yervoy combination were alive after two years, outperforming chemotherapy as a first-line treatment. Opdivo and Yervoy compete with rival drugs from companies such as Merck & Co and Roche in several types of cancer.
Merck's Keytruda dominates the highly lucrative market for newly diagnosed advanced lung cancer. Shares of the company fell 2.6per cent to US$82.30 following the Bristol-Myers news.The interim analysis builds on the positive results the Opdivo-Yervoy combination has previously shown in melanoma and renal cell carcinoma, said Bristol-Myers, adding that it will present full data from the trial at an upcoming meeting.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »